Hemostemix Inc. (CVE:HEM – Get Free Report)’s share price reached a new 52-week low on Monday . The stock traded as low as C$0.04 and last traded at C$0.04, with a volume of 5000 shares trading hands. The stock had previously closed at C$0.05.
Hemostemix Trading Down 11.1 %
The firm has a market cap of C$3.59 million, a price-to-earnings ratio of -1.13 and a beta of 0.55. The stock’s fifty day moving average price is C$0.07 and its 200-day moving average price is C$0.07.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia in Canada and the United States.
Featured Articles
- Five stocks we like better than Hemostemix
- Investing in Travel Stocks Benefits
- The 3 Hottest Insiders Buys This Month
- Best Stocks Under $5.00
- What Bulls and Bears May Be Getting Wrong about SOFI Stock
- How to Find Undervalued Stocks
- Microsoft Analysis: Trends, Predictions & Investment Insight
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.